

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Prospect Manchester Hospital, Inc. d/b/a The Manchester Memorial Hospital</p>		<p>In accordance with letter dated October 31, 2016</p>	<p>4. Expiration Date: March 31, 2024</p>
<p>2. 71 Haynes Street Manchester, CT 06040</p>		<p>3. License number: 06-03413-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-01253 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 500 millicuries total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300.</p>

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
06-03413-01

Docket or Reference Number
030-01253

Amendment No. 47

- | | | | |
|---|---|---|---|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>D. Iodine-125</p> | <p>7. Chemical and/or physical form</p> <p>D. Sealed Sources (Isoaid, Model Model 1A1-125A; IsoStar Texas, Inc. d/b/a Imagyn Medical Technologies, Model Model IS-12501; Medi-Physics, Model Model 6711; North American Scientific, Model Model MED 3631; Source Tech Medical, Model Model STM 1251; Theragenics Corporation, Model AgX100)</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>D. 500 millicuries total</p> | <p>9. Authorized use</p> <p>D. For any manual brachytherapy procedure permitted by 10 CFR 35.400.</p> |
|---|---|---|---|

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 71 Haynes Street, Manchester, Connecticut.
11. The Radiation Safety Officer for this license is Edward Denstman, M.D.
12. A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User(M.D.,D.O.,etc.)</u> | <u>Material and Use</u> |
|--|-------------------------|
| Edward Denstman, M.D. | 35.100 35.200 35.300 |
| Gary W. Kravetz, M.D. | 35.100 35.200 35.300 |
| Arthur A. Ostrowitz, M.D. | 35.100 35.200 |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

06-03413-01

Docket or Reference Number

030-01253

Amendment No. 47

Authorized User(M.D.,D.O.,etc.)

Material and Use

Ted Stuart Metzger , M.D.

35.100 35.200

Edward M. Rosenblatt, M.D.

35.100 35.200

Frederick J. Shuler, M.D.

35.100 35.200

Christopher Taubes , M.D.

35.100 35.200

Robert Dowsett, M.D.

1125 for procedures permitted by 35.400

Jacqueline M. Lyon, M.D.

1125 for procedures permitted by 35.400

Andrew L. Salner, M.D.

1125 for procedures permitted by 35.400

Helaine Bertsch, M.D.

1125 for procedures permitted by 35.400

Kenneth Leopold, M.D.

1125 for procedures permitted by 35.400

Timothy S. Boyd, M.D.

1125 for procedures permitted by 35.400

Vinay Madan, M.D.

35.100 35.200

Thomas Kilkenny, M.D.

35.100 35.200

Stephen H. Hauser, M.D.

1125 for procedures permitted by 35.400

Susan Y. Kim, M.D.

1125 for procedures permitted by 35.400


13. The effective date of License Amendment 46 is the date that the license transfer described in the letter dated June 6, 2016 (ML16159A359), is completed, but no later than 30 days after the NRC approval letter dated September 30, 2016.
14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents,

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
06-03413-01Docket or Reference Number
030-01253

Amendment No. 47

including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated October 21, 2003 [ML033100341]
- B. Letter dated February 11, 2014 [ML14059A117]
- C. Letter dated June 6, 2016 [ML16159A359]
- D. Letter dated September 30, 2016



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: January 17, 2017By: Robert L. Gallagher
Robert Gallagher
Region 1